Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01840540 · ClinicalTrials.gov registry record · Phase 1
MSC for Occlusive Disease of the Kidney
A Phase 1 study of Renovascular Hypertension and Atherosclerotic Renal Artery Stenosis, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT01840540: Completed Phase 1 study of Renovascular Hypertension and Atherosclerotic Renal Artery Stenosis, sponsored by Mayo Clinic.
NCT01840540 is a Phase 1 study of Renovascular Hypertension and Atherosclerotic Renal Artery Stenosis that has completed, run by Mayo Clinic. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01840540, a Phase 1 study of Renovascular Hypertension and Atherosclerotic Renal Artery Stenosis, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the safety and toxicity of intra-arterial infused autologous adipose derived mesenchymal stromal (stem) cells in patients with vascular occlusive disease of the kidney.
Primary Outcome
Individual kidney blood flow, measured by multidetector CT contrast transit times, will be measured before and after MSC infusion.
Conditions Studied
Interventions
- DRUG Arterial infusion of autologous mesenchymal stem cells
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-04 |
| Est. Completion | 2017-04 |
| Phase | Phase 1 |
What the finished NCT01840540 record still lists
NCT01840540 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 3 conditions, with Renovascular Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Arterial infusion of autologous mesenchymal stem cells is the first listed.
NCT01840540 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT01840540 about?
NCT01840540 is a clinical study titled "MSC for Occlusive Disease of the Kidney". To determine the safety and toxicity of intra-arterial infused autologous adipose derived mesenchymal stromal (stem) cells in patients with vascular occlusive disease of the kidney.
What is the current status of trial NCT01840540?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2013-04. Estimated completion is 2017-04.
What conditions does trial NCT01840540 study?
This clinical trial studies the following conditions: Renovascular Hypertension, Atherosclerotic Renal Artery Stenosis, Ischemic Nephropathy.
What interventions are being tested in trial NCT01840540?
The interventions under investigation include: Arterial infusion of autologous mesenchymal stem cells (DRUG).
Who is sponsoring clinical trial NCT01840540?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01840540 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renovascular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01840540's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia